Saturday, October 31, 2026

Matterport Stock Over 9% Down So Far Today

Matterport
 Stock Over 9% Down So Far Today

(VIANEWS) - Shares of Matterport (NASDAQ: MTTR) dropped 9.05% to $2.66 at 14:27 EST on Friday, after two successive sessions in a row of losses. NASDAQ is rising 0.93% to $13,223.43, following the last session's upward trend. This seems, up to now, a somewhat positive trend exchanging session today.

Matterport 's last close was $2.92, 60.78% below its 52-week high of $7.45.

About Matterport

Matterport, Inc., a spatial data company, focuses on digitization and datafication of the built world. The company offers Matterport Capture Services, a fully managed solution for enterprise subscribers; Smartphone Capture, a smartphone capture solution for both iOS and Android; Matterport Pro3, a 3D camera that scans properties; Matterport Pro2, a 3D camera that captures spaces; and 360 Cameras. It also provides Matterport Axis, a motorized mount that can be used with the Matterport Capture app to capture 3D digital twins of any physical space with increased speed, precision, and consistency. It offers solutions for residential and commercial real estate, facilities management and retail, AEC, insurance and repair, and travel and hospitality. Matterport, Inc. is headquartered in Sunnyvale, California.

Earnings Per Share

As for profitability, Matterport has a trailing twelve months EPS of $-0.84.

Sales Growth

Matterport 's sales growth is 37.8% for the current quarter and 16.2% for the next.

More news about Matterport (MTTR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com